Skip to content

Earnings call

Narayana Hrudayalaya Q1 FY27 earnings call: OP consults across Narayana Hrudayalaya’s clinic network grew about 30% year-on-year

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

OP consults across Narayana Hrudayalaya’s clinic network grew about 30% year-on-year. Patient footfalls in Narayana Hrudayalaya’s clinics are approximately 30% of total OPD footfalls in the hospital. The company has committed INR 3,000 crores to projects over the next two years; part will be its own contribution and part will be borrowing, and the cash will be deployed towards projects.

The numbers management gave

Results

  • OP consults across Narayana Hrudayalaya’s clinic network grew about 30% year-on-year.
    Show source
    So, in terms of overall transactions in terms of OP consults, these have grown to about grown by about 30% year-on-year.
  • Clinic network had about 66,000 consultations in the quarter.
    Show source
    And in the quarter, we did about 66,000 consultations across our clinic network.
  • High volumes of high-end procedures and increased use of technology and robotics drove margin improvement over the last two, three quarters.
    Show source
    So , if you see the margin improvement over the last two, three quarters, they are essentially on account of high volume of high -end procedures and also increased use of technology and robotics.

Money and capital

  • The company has committed INR 3,000 crores to projects over the next two years; part will be its own contribution and part will be borrowing, and the cash will be deployed towards projects.
    Show source
    We've committed INR 3,000 crores.

What it expects ahead

What management expects

  • The company will see expansion in the core operating margin of the business from leverage benefits, but it is not possible to give a projection.
    Show source
    It is not possible to give a project ion on that, but what we can definitely see is that we will see expansion in the core operating margin of the business, given the leverage benefit that we will enjoy.
  • The company has no particular definite number to disclose as a ROCE target for the UK assets.
    Show source
    We would like to have the international questions in the second half, but since you have asked, I think as we said during the acquisition time itself, we do not have any particular definite number to disclose as a ROCE target.
  • The company believes the UK assets were acquired at a very reasonable price and offer substantial opportunity to improve earnings without significant further capital deployment in that market, using the existing capital base.
    Show source
    Having said that, we believe that the assets were acquired at a very reasonable price and there is a substantial opportunity for us to improve their earnings compared to where they are now and when we acquired it, without any significant further capital deployment in that market with the existing capital base that already exists.
  • Clinics are ahead of plan, while its insurance business is slightly behind; the company will continue to reassess every few quarters whether the ecosystem benefits materialize.
    Show source
    Page 7 of 17 Narayana Hrudayalaya Limited August 03, 2026 Things are on track, especially ahead of plan with the clinics, slightly behind with the insurance, but every few quarters or so, we'll continue to reassess if the ecosystem benefits do materialize.
  • Insurance business is too small to judge now.
    Show source
    Insur ance is too small to judge now.
  • The company thinks the worst of the heat wave’s impact on Cayman hospitals is behind it as the season changes towards mid and end of Q2, and hopes the impact will be a one-off.
    Show source
    But this is definitely something that hit us pretty bad, but hopefully it'll be a one-off.
Show 2 more statements

What management expects

  • The company says its UK business is better off on private-versus-NHS mix than when acquired, but not enough to comment on; it will consider how to convey progress on diversifying the payor mix after a few more quarters.
    Show source
    We are better off there, but not enough to comment on.
  • Early results with the clinics are encouraging. Replaced by a later filing.
    Show source
    The early results are encouraging with the clinics.

What it is building and selling

Projects and capacity

  • Some of Narayana Hrudayalaya’s asset-light partner model projects are running slower because of licensing issues on the partner side; the company is in discussion with the partners and expects the issues to be sorted in the next month or so.
    Show source
    There are a couple of asset -light partner model projects, which are running a bit slower, specifically because from the partner side in terms of certain licensing issues, the delays, licensing, which obviously we are in constant discussion with them, and i t should get sorted in t he next month or so.
  • Southwest Bangalore project is at the end stage of construction, and the company is hopeful to start it by the end of Q2.
    Show source
    And when it comes to the project in Southwest Bangalore, as I said, we are at the end stage of th is construction and we are hopeful to start it by the end of Q2.

Segments

  • Patient footfalls in Narayana Hrudayalaya’s clinics are approximately 30% of total OPD footfalls in the hospital.
    Show source
    If you look at the data of clinics, clinics we do more or less, the total footfalls of patients in clinics is approximately 30% of the total OPD footfalls in the hospital.
  • The company considers the acquired UK business’s 95% NHS mix undesirable; its closest peer in geographical distribution has approximately 70% NHS, which is closer to the company’s desired mix.
    Show source
    The closest peer in terms of geographical distribution has about 70% NHS, approximately, so that's closer to where we want to be.
  • When Narayana Hrudayalaya acquired the UK business, its payor mix in value terms was approximately 95:5 between NHS and private payors.
    Show source
    Anesh Shetty: Yes, in value terms like we said, when the business was acquired, it was approximately 95 :5.
  • The clinic network, mainly around Bangalore, strengthened the hospital network’s brand reputation, resulting in increased footfall.
    Show source
    And also, if you see the presence of our clinics across the network, in mainly around Bangalore, has actually strengthened the brand reputation of the hospital network, resulting in increased footfall.

Risks, rules and outside factors

Outside factors

  • A widespread, severe heat wave caused Cayman hospitals’ chillers and air conditioning units to fail frequently, costing them several days of operating capacity; heat-wave-affected days continued into Q2.
    Show source
    For us, what that meant is the chillers and air conditioning units in the hospitals conking off quite often, and we lost several days of operating capacity, which in a business with a baseline low margin can be quite catastrophic.

Rules and policy

  • UK medical software may be classified as software as a medical device depending on how it is used, requiring certification; this adds approximately 4 to 6 months to the timeline initially anticipated for Narayana Hrudayalaya’s software products, as a one-time effort.
    Show source
    Having said that, I think it adds about, I'm going to be approximate here, about 4 to 6 months in terms of timeline to what we initially anticipate d. But it's a one- time effort, and the advantage it gives us is that there are very few products at our scale that have all the classifications to be used as software as a medical device in the UK.
  • The company believes very few products at its scale have all the classifications needed to be used as software as a medical device in the UK.
    Show source
    Having said that, I think it adds about, I'm going to be approximate here, about 4 to 6 months in terms of timeline to what we initially anticipate d. But it's a one- time effort, and the advantage it gives us is that there are very few products at our scale that have all the classifications to be used as software as a medical device in the UK.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Prithvi Raj: Hi. This is Prithvi Raj from Unifi Capital. Let me begin with the domestic hospital business first. I think the EBITDA growth of 40% despite not adding any beds in the last 7 to 8 years is quite remarkable. In this context, my first question is with respec t to the revenue growth. I think till last few quarters, entire revenue growth for India hospitals came from ARPOB, but this time, surprisingly, even the footfalls went up. So , could you explain that, and how should we look at it going forward? Will it be a combination of ARPOB plus footfalls or it will be predominantly ARPOB till you commission the new hospitals?

    Answer, r venkatesh

    R. Venkatesh: Hi, Prithvi Raj. I'll take this up. We've been off late doing a lot of high -end procedures and also the robotics has gone up substantially. So , if you see the margin improvement over the last two, three quarters, they are essentially on account of high volume of high -end procedures and also increased use of technology and robotics. And also, if you see the presence of our clinics across the network, in mainly around Bangalore, has actually strengthened the brand reputation of the hospital network, resulting in increased footfall. If you look at the data of clinics, clinics we do more or less, the total footfalls of patients in clinics is approximately 30% of the total OPD footfalls in the hospital. So that is also the level of contribution the clinics are doing.

    Answer, r venkatesh

    That is also comple mented towards increasing of the footfall, and overall general demand is also strong as far as healthcare is concerned. So, we have seen a good traction in terms of volumes coming across the network, across all the regions. And it has been a good combination of volumes as well as realizations. And going forward, we would strive towards continuing with such a combination in the quarters to come. But obviously, we will not be able to boil down to any specific numbers, but we would always work towards getting a combination of both volumes and realizations in the quarters to come.

  2. Question

    Prithvi Raj: That is clear. Just on margins front, you made a point of the 24% EBITDA margin. See, if we compare your ARPOB with other competitors, it is significantly lower. However, your margins are largely on par with the competitors. And as you have taken several initiatives on efficiency, etcetera., but do you think is there a further scope for hospitals' margins to go up or it should stabilize at these levels?

    Answer, sandhya j

    Sandhya J: Yes. Sure, Venkatesh. If you look at how our margin journey, like you had acknowledged that we haven't added any beds, but we have been able to deliver incremental revenue and throughput. And that is what is giving us the expansion that we are seeing in margins in addition to footfalls that Venkatesh talked about. Page 2 of 17 Narayana Hrudayalaya Limited August 03, 2026 This will continue because we don't have any meaningful bed addition coming in for the next two to three years. Having said that, we have to make a choice on the leverage benefit. We are an operator that works with an affordable care philosophy, so we will continue to make that choice on how much do we pull back into cash flows and thereby fueling our expansi on initiatives?

    Answer, sandhya j

    How much we are going to continue to invest into our new growth verticals like integrated care, and how much we will pass back to the customers. And those operational decisions we will make as we go through this journey. It is not possible to give a project ion on that, but what we can definitely see is that we will see expansion in the core operating margin of the business, given the leverage benefit that we will enjoy.

  3. Question

    So how much of the claims are coming to your own hospital chain and how much of the claims are going to third -party hospitals at this point of time? And is that a reason what explains the higher losses?

    Answer, ravi vishwanath

    Ravi Vishwanath: So maybe I can take that and others can chime in if you want . So, a couple of things on this, right? I don't think we are prepared at this point in time to disclose some of those numbers. Having said that, as Venkatesh was talking about for the clinics business, for example, similarly the insurance business has a lot in terms of brand visibility for the group. And as these customers come in and as we get more and more engagement with these customers and introduce them to the entire gamut of services that Narayana Health provides, over time, we believe that we feel confident that they will consider NH for all their advanced diagnostics and hospitalization needs. And we will see a large portion of people coming to our hospital. Having said that, in our group policies at the moment, we would, we do offer people choice.

    Answer, ravi vishwanath

    And, we are working hard to win, these customers to our hospitals by making sure they get great service in the hospital, making sure that the overall experience they have is good and engaging deeply with them to ensure that that our hospital is at the top of their mind when they're considering their hospitalization needs. So that is kind of where we are We do have a difference, more I mean, broadly what I can tell you is that on the retail side, a lot of our customers come to our come to our hospitals by choice. And on the group side, we are seeing those numbers improving. But we continue to work on that and to be top of mind for our customers to consider NH when they require hospitalization.

  4. Question

    Jaspreet Singh: What is the ROCE of our UK business currently?

    Answer, sandhya j

    Sandhya J: So, I think it is too early to measure the ROCE of the UK business at the moment. It is very early days for us. We just acquired that business, so we can start reporting this maybe four quarters from now.

  5. Question

    Jaspreet Singh: Is there any target by 2030, so any milestone that we will achieve that we can say UK asset is seen as a good capital allocation? Is there any targets?

    Answer, anesh shetty

    Anesh Shetty: Yes. Thank you, Jaspreet. We would like to have the international questions in the second half, but since you have asked, I think as we said during the acquisition time itself, we do not have any particular definite number to disclose as a ROCE target. Having said that, we believe that the assets were acquired at a very reasonable price and there is a substantial opportunity for us to improve their earnings compared to where they are now and when we acquired it, without any significant further capital deployment in that market with the existing capital base that already exists. Page 4 of 17 Narayana Hrudayalaya Limited August 03, 2026 Moderator: Thank you.

  6. Question

    Sajal Kapoor: Yes. Hi, team. This is Sajal from Antifragile Thinking, and thanks for giving me this opportunity. My first question is, what evidence do we have today that owning both insurance and care delivery gives Narayana a structural underwriting advantage rather than simply transferring economics between insurer and the hospital?

    Answer, anesh shetty

    Anesh Shetty: Yes, so hi, Sajal. Thank you for your question. So just to clarify, sorry, due to a prior travel commitment and some delays there, Emmanuel is unable to attend this call, so he sends his apologies. To your question, I think just keeping the underwriting advantage aside for now, if you look at our actual experience in a very short time, where we have the largest cluster of clinics is in Bangalore. And the footfalls, the outpatient footfalls in those small clinics in aggregate represents a little over a third of what we see in our flagship hospital in Bangalore, including the HSR second hospital in Bangalore as well. Now, when we look at the referral potential and what we are actually seeing being referred in, it is a phenomenal driver of activity, volume, and empowering a lot of the growth we are seeing in our in our footfall and conversions, especially around the high-end complex procedures, robotic surgeries, etcetera., the complex cardiac interventions and so on. To your second question about the underwriting model itself, now there is very little medical underwriting happening in the insurance industry as we speak.

    Answer, anesh shetty

    We have an ability to understand the consumption patterns through the people who are subscribers for our clinics. We render the bulk of their primary care, the bulk of their pharmaceutical needs, the bulk of their diagnostic and follow-up care. This really gives us an ability to understand where people are spending, what are they spending on, and how can we best position ourselves to cater to that. Now, obviously, this is a longer-term play, while we have started seeing very encouraging results with the clinics and the subscription plans, insurance, as Ravi mentioned, is early days, it is a small book. These things will play out, but the early signs do point to us having something interesting to work on where we do have an inherent structural advantage to somebody just selling an open-ended policy to anyone who fulfills certain criteria.

  7. Question

    Sajal Kapoor: No, that's helpful, Anesh. I mean, just a quick follow-up on that one. So some of the patients would have renewed their policy, right? And given their past behavior, we potentially understand them a little better in terms of what kind of system they have in terms of their own sort of mental and physical well-being as well as their pattern of submitting a claim, and how does that reflect in the pricing for the renewal? And that's one. And then as a system, we are continuously learning because, yes, it is a smaller book and early days for us. How is that learning getting reflected in our underwriting decision-making for the new patients that were never part of our network? Page 5

    Answer, anesh shetty

    For a good number of our patients, given our role as both a provider and insurer, we actually are the only people who can underwriting them and price out the policy as well as a renewal to reflect their changing health status. But Ravi, do you want to take Sajal's question?

    Answer, ravi vishwanath

    Ravi Vishwanath: Yes, certainly. So a few things, Sajal. So one thing just to keep in mind and kind of be very clear about, right, is that in India at the moment, at least, we can’t change somebody's renewal premium based on let's say deterioration in their health, right? So that's one thing to keep in mind, and we, of course, do not do that. Having said that, let's think about how this benefits us, over a period of time, right? There are two parts to this. One is while I may not be able to change prices at an individual level, what this gives me a very good sense of is what is happening at a portfolio level, at my overall group retail portfolio, and at a group policy level.

    Answer, ravi vishwanath

    I have a good sense of what the claims are going to be next year. When you typically underwrite a group policy, right, you have some information and it is kind of imperfect that most companies would underwrite with. In our case, we have a good idea of what claims have already happened and are unlikely to repeat next year, what claims haven't happened yet, but we know are going to happen next year. And price our renewal group at a group level accordingly and make changes at the price level as per the requirements of at a portfolio level, right? So that is a significant advantage that we have. And as our policies come to renew, right, we have just started getting into renewal cycle in our renewal on our retail book and have got three policies so far renewed on the group side and more to come. And we see that this is becoming something that is becoming more and more valuable to us.

    Answer, ravi vishwanath

    The other part is that is the entire engagement that we do with customers. So if you think about it in a slightly different way from a customer's perspective, right, what do we bring to the table for the customer? We allow because we understand their health, unlike another insurance company, we can actually intervene earlier, and we can send somebody to the hospital and recommend that do the surgery now. It is better for the customer. It is hopefully less complicated, it is quicker recovery, and it is a lower cost for the insurance company as well. So, there is a number of things here that play that allow us to impact the life of the customer in a very positive way, while also managing our overall book in a sustainable way. And that is the unique thing that we have as an insurance company that is promoted by a hospital, the only insurance company that is promoted by a hospital.

  8. Question

    Sajal Kapoor: That's helpful. Thank you. And my second question, it is related to a classic tension. So when the hospital benefits from doing more and insurer benefits from doing less, how does Narayana decide what is optimal for the system as a whole?

    Answer, anesh shetty

    Anesh Shetty: In the short run, there is a conflict, but in the long run, if the hospital does too much, the insurance arm will not be sustainable. If the hospital does too less, then that's also not good for the long-term outcomes of the patient. Page 6 of 17 Narayana Hrudayalaya Limited August 03, 2026 So in a short run, yes, one quarter or two, but in a long-term sustainable way, if you look at integrated care models all across the globe, it is a self -check mechanism where you render the right amount of care, not too much, not too less. But more importantly in our market where there is abundant choice, if the insurance company if the insurance clients perceive that you are denying care or you are not rendering enough care, they will leave and go, which defeats the entire purpose.

  9. Question

    Nishant Singh: Are you able to see that question?

    Answer, ravi vishwanath

    Ravi Vishwanath: I am. I will just read that out for people's benefit and quickly answer that. We did cover this a little bit earlier as well. So out of all the patients admitted in the hospital this quarter, what percentage originated through our insurance platform compared with traditional referral channels? The first part of the question. Again, we're not prepared at this point to share the percentages, although we track it very, very diligently. But again, the insurance book is still a small book and it will take some time before we see, really significant impact, but that is, of course, the direction that we all are working towards.

    Answer, ravi vishwanath

    The second part of the question is, as the book matures and underwriting, we expect underwriting profitability to improve through premium increases, better risk selection, or lower operating expenses? I would say that our prior in order of first of all, all three. And in order of priority, I think it's very important for us and consistent with our overall approach as a group to have the lowest possible operating expenses to give the maximum possible benefit back to the customer. That will continue to be a focus, and you've seen a significant drop in our expense ratio, from previous periods, and something we'll be working on very, very closely. Better risk selection, just as a response to the earlier conversation we spoke question, we spoke a little bit about that. And the premium increases, will be a fact of life based on how the book performs, and, our approach is going to be to be responsible in our pricing and, keep doing that and make sure that we are not overpriced or underpriced and trying to be as correctly priced as possible in order to have a sustainable business, which means value proposition for the customer as well as a sustainable pricing for ourselves. On the second part, maybe I'll defer to Sandhya or Anesh on that, insurance sitting inside a listed company.

    Answer, anesh shetty

    Anesh Shetty: Yes, sure. So the question is, it sits inside the listed company and therefore suppresses consolidated return metrics. Has the board internally defined a maximum acceptable period of cumulative investment after which the strategy would be reassessed? It's a combination of both timeline and cumulative investment, as we did mentioned, we did set out broadly the terms in terms of the amount of investment we were willing to make into this. Page 7 of 17 Narayana Hrudayalaya Limited August 03, 2026 Things are on track, especially ahead of plan with the clinics, slightly behind with the insurance, but every few quarters or so, we'll continue to reassess if the ecosystem benefits do materialize. The early results are encouraging with the clinics. Insur ance is too small to judge now.

    Answer, anesh shetty

    We'll continue to watch and reassess every few quarters or so.

  10. Question

    Rajit Aggarwal: Hi. In your presentation, you mentioned there are three projects which have got postponed from FY28 to FY29, two to FY29, one to FY30. So what are the reasons for this postponement, if you can share? And also, Southwest Bangalore, the 100 beds which are su pposed to come during the current financial, which quarter do you expect them to operationalize?

    Answer, r venkatesh

    R. Venkatesh: Yes, I'll take this. See, among all the projects which we have listed out, most of the projects are within the acceptable timeline. Even if there's a slight delay, they are within that 6 -month window period of acceptable timeline. There are a couple of asset -light partner model projects, which are running a bit slower, specifically because from the partner side in terms of certain licensing issues, the delays, licensing, which obviously we are in constant discussion with them, and i t should get sorted in t he next month or so. So they should cut those delay by a considerable period of time. So this is minor delay, but other than that, most of these projects ar e within the acceptable limits. And when it comes to the project in Southwest Bangalore, as I said, we are at the end stage of th is construction and we are hopeful to start it by the end of Q2.

    Answer, r venkatesh

    So this is also fully in line with our plans, and we hope to have this start by end of Q2. Rajat Agarwal: Okay. Thank you.

    Answer, ravi vishwanath

    Ravi Vishwanath: Right. I'll attempt to answer that. At this point, we don't make, future forecasts, but I think the important thing here is a couple of things. As I laid out in the earlier response, there are a number of things that we will continue to do to make sure that the portfolio itself is something that is managed sustainably. That includes a number of things around underwriting and claims, as well as the type of business that we are writing. The nature of insurance business and the way that it is currently accounted is that you are able to book a fraction of your revenue in the period, and then, but you have to book the entire expenses. So growth comes with, it does have an impact on P&L, but these are all things that we look at closely and monitor.

    Answer, ravi vishwanath

    Page 8 of 17 Narayana Hrudayalaya Limited August 03, 2026 I think the important thing for us is to have a long -term sustainable portfolio and over time to engage with our customers across primary care that we provide them as part of the insurance offering and as part of value - added services, so that the entire in tegrated care approach comes in, and we're able to see as a group the value of having hospital, clinic, insurance together working with customers to he lp them get well, stay healthy. So that's kind of how we're going to be approaching this. We are, of course, we're obviously very focused on a sustainable business. At this point in time, I think it’s, given the size of the portfolio and the volatility, it's a little bit too soon to talk about when is it going to get to various levels, but it's something that we'll keep working on and keep updating you each quarter. Om: Got it, Raviji. Just to add on to the same, so earlier we had a bit of more targeted segment was the retail. Now as you indicated that we have been also looking somewhere on the group and the other segment of, the sector as well.

    Answer, ravi vishwanath

    Where do you see this shaping up in two to three years? I'm not talking about from profitability point of view. Just want to get a view from scalability perspective. Do you see, Narayana Health Insurance becoming a prominent player in terms of, the other competitors as well for the health insurance sect or?

    Answer, ravi vishwanath

    Ravi Vishwanath: I don't know what you mean by prominent. I mean, if you think about the impact that we will have on the lives of our customers and be able to provide an entire integrated approach across everything that our customer requires from a healthcare perspective, then as Narayana Health, I think we'll be very, very, very prominent in the life of that customer. And that's what we're trying to build. Okay ? And I think that's our focus. But in terms of, channels and distribution, our focus I would imagine would continue to be on those areas where we think we can make the most impact in the life of our customer, which for us at the moment appears to be retail coverage as well as SME. These are areas where there is a lot of people who are left uncovered, who for whom having insurance will make a real difference in their life, will stop pushing them into, below the poverty line, should they require, should there be a catastrophe or not b e able to access care.

    Answer, ravi vishwanath

    That's what we are focused on. But in terms of prominence, I don't think we look at it as a market share thing. It's about how can I provide a complete integrated service across clinics, hospitals, and insurance to our customers so that we can be super prominent in their life, and if we make that impact and do that over a period, to as many people as we can, then I think we'll make a real difference. Om: That's very well. And to achieve that, we will be strictly sticking to the Narayana integrated ecosystem, right? So we are only targeting on that area, we are not going to pursue this as a separate entity?

    Answer, ravi vishwanath

    Ravi Vishwanath: The question that you asked was over a period of time, right? So look, we are always going to be looking at opportunities and looking at what makes sense, but the lens is always going to be an overall integrated lens. That is the unique thing that we bring to this market, and that's what we're going to be focusing on. And all opportunities, all ideas, new things that we'll invent are all on the table to help us drive that goal. Om: Thank you, Raviji. All the best. Page 9 of 17 Narayana Hrudayalaya Limited August 03, 2026 Moderator: Thank you.

Show 10 more questions
  1. Question

    Jaspreet Singh: Sir, just on the UK ROCE, my will it be better than what we have achieved in Indian and Cayman business? UK ROCE, will it be better than that?

    Answer, anesh shetty

    Anesh Shetty: Yes. We'd like to take the UK questions in the second half, but since you've asked, it's still early days, Jaspreet, to answer that question definitively. But like we said, before, we do perceive a very good opportunity to increase margins for the capital we have I mean, disproportionate to the capital we've deployed. It's a country that has a lot of favorable economic in terms of how the business is structured, and especially our advantage of being a low-cost provider. But to your specific question it's too early to have a definitive number and a definitive timeline compared to where we are currently.

  2. Question

    Jaspreet Singh: Yes, yes.

    Answer, sandhya j

    Sandhya J: Okay. So, this will get deployed into the projects that we've committed over the next two years. We've committed INR 3,000 crores. A part of that will be our own contribution and a part of it will be borrowing in nature. So we will deploy that cash towards projects.

  3. Question

    Jaspreet Singh: Where this cash has come from, there is significant increase in the cash, like from ‘25 to ‘26. Where this has come from?

    Answer, sandhya j

    Sandhya J: The cash has entirely come from the performance of the operating business in India and Cayman. Jaspreet Singh: Okay. Thank you.

    Answer, sandhya j

    Sandhya J: I think we can take the questions on the chat, Nirav, and then move to UK, so we can finish off all the India questions on the chat.

  4. Question

    Nishant Singh: There's a question on the overall losses, loss funding for insurance, clinic business put together. This we've already covered.

    Answer, sandhya j

    Sandhya J: Answered. Nishant Singh: The rest are mostly for international businesses. Can you provide some color on the trend in patient transaction volumes across your clinics this quarter?

    Answer, ravi vishwanath

    Ravi Vishwanath: Yes, certainly. So, I mean, in terms of the overall transactions that we have across clinics, I mean, this is something that continues to be positive. Just give me a moment and I'll just pull up the some of the numbers here for you. Right. So, in terms of overall transactions in terms of OP consults, these have grown to about grown by about 30% year-on-year. And in the quarter, we did about 66,000 consultations across our clinic network. So that is something that has been, pretty encouraging.

    Answer, ravi vishwanath

    A very high percentage of our customers, again, we don't share the exact number, but a very high percentage, well over a significant number, of the revenue of the clinics comes from these members. And so that's been very encouraging. So our clinic business continues to grow. We are opening two more clinics this quarter and breaking ground on more later. So, we are quite excited about the direction that the clinic business is going, both at the clinic level, as well as the support that is provided to the hospital, as well as our insurance business. So the entire integrated story that we've been building for the last couple of years is coming, is starting to play out and we're pretty excited with the direction on that.

  5. Question

    Nishant Singh: There is a question on the domestic market which Anesh can answer. How do you see competition because every other hospital is adding beds and why don't you expand your network in states like UP, Bihar, where organized players like Max, Medanta, Fortis has they have no presence? Page 11 of 17 Narayana Hrudayalaya Limited August 03, 2026 Anesh Shetty: Yes, thank you.

    Answer, anesh shetty

    Yes, sure. Thank you for the question, whoever asked it. We continue to evaluate all opportunities in India, especially states that are underpenetrated like you mentioned. Having said that, our focus now with the current wave of capital deployment and expansi on is in the clusters where we are already strong, already have an established presence, and we have a track record of delivering and establishing our brand. We have outlined over the next 3 financial years or so, how that capital deployment will look like. And once we start Phase 2, following some progress on Phase 1, we will consider newer markets and newer geographies. We currently do not have a presence in the states mentioned.

  6. Question

    Nishant Singh: There's a question which Sandhya will answer. Is the Q1 FY27 EBITDA margin decline temporary due to integration cost or should we consider this the new normal for the consolidated business?

    Answer, sandhya j

    Sandhya J: So, I'd like to take this in three parts actually. If you look at the India business per se, including combining the losses from the clinic business, even if you set that off, the net margin has expanded by 400 bps year -on- year. So there, I think there is no shrinking, in fact, it's a very strong performance. Cayman hospital has come back to its earlier levels and has been because of the ramp-up and is operating at optimal margins. There are three places where there is a cash burn. One is Cayman Insurance, India Insurance. Cayman Insurance, we'll speak about when we come to the Cayman segment.

  7. Question

    Prithvi Raj: And moving on to the Cayman hospitals, I mean, the growth this quarter in USD terms is a bit soft in like 6%. The whole point of getting into insurance is that it will also add more footfalls to the hospital. So is there any specific reason for this low growth in Cayman hospitals this quarter or is it more to do with couple of surgeries getting delayed which explains this?

    Answer, anesh shetty

    Anesh Shetty: So to your first question, on a -- there will always be seasonal variation, but on a year-on-year basis, which we'll have to compare to the period prior to acquisition, there is about a 5% year-on-year revenue growth. It would have been higher, however, as you would have read in the media, there was a widespread heat wave, which was very severe in all across the country. Critical infrastructure, not only hospitals, but railway operators and other infrastructure, was significantly impacted. For us, what that meant is the chillers and air conditioning units in the hospitals conking off quite often, and we lost several days of operating capacity, which in a business with a baseline low margin can be quite catastrophic. So, we unfortunately have some of those heat wave impacted days even in Q2. Hopefully, towards the mid and end of Q2 we -- the season changes and we think that the worst is behind us. But this is definitely something that hit us pretty bad, but hopefully it'll be a one-off.

  8. Question

    Nishant Singh: Thanks, Sandhya. Anesh, there's a related question to it's a follow -up question to your answer last. Can you elaborate what you mean by longer regulatory approval timelines for the own software products?

    Answer, anesh shetty

    Anesh Shetty: Sure. So to deploy software in in the UK medical software, it frequently gets classified, depending on how you use it, as software as a medical device, which has a certification timeline. We knew that there were certain regulatory and data privacy processe s to go through pre-acquisition, but we did not have the details about how our software would be classified. Having said that, I think it adds about, I'm going to be approximate here, about 4 to 6 months in terms of timeline to what we initially anticipate d. But it's a one- time effort, and the advantage it gives us is that there are very few products at our scale that have all the classifications to be used as software as a medical device in the UK. Nishant Singh: Thanks, Anesh. There's a question on the UK business being showing high dependence on the NHS contracts. What if I think we've already covered?

  9. Question

    Nishant Singh: No, I'm saying you've already covered on the margins and how the future will look like, but maybe you can mention about this dependency on the NHS. Page 16 of 17 Narayana Hrudayalaya Limited August 03, 2026 Anesh Shetty: Yes, the business we acquired was 95% NHS.

    Answer, anesh shetty

    That's definitely not good and not where we want it to be. The closest peer in terms of geographical distribution has about 70% NHS, approximately, so that's closer to where we want to be. It obviously will take t ime to get there. We did anticipate this to take 4 to 5 years to move. Early results are promising. We have had some encouraging signs, but it's a journey because the doctor engagement model, insurance relationships, even the location and structure of these hospitals, which you cannot change in the short term, everything has to be redone. But it is a wor thwhile pursuit because it does come at a meaningfully higher per-unit realization.

  10. Question

    Nishant Singh: One more question, they are asking if you can give a split of the private versus NHS in value or volume terms?

    Answer, anesh shetty

    Anesh Shetty: Yes, in value terms like we said, when the business was acquired, it was approximately 95 :5. We are better off there, but not enough to comment on. What we can do is once we have a few more quarters under the belt, we'll think about the appropriate way to convey progress on diversifying payor mix.

Questions about this call

When was the Narayana Hrudayalaya Q1 FY27 earnings call transcript filed?
Narayana Hrudayalaya filed the transcript with the exchange on 10 Aug 2026. This page is built from that transcript.
What does this page list?
21 statements from the transcript across 7 topics, 7 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 20 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Narayana Hrudayalaya Q1 FY27 concall: OP consults across Narayana Hrudayalaya’s clinic network grew about 30% year-on-year · DalalOS